Potassium ： Cardiac Arrhythmia

C エビデンス小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dpotassium\u0026condition\u003Darrhythmia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Key Study Findings

Other n=19 1 weeks

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.

Dose: 50 mg vs: baseline Outcome: cardiac repolarisation 効果: None p=0.07

対象集団: lqts with a disease-causing kcnq1 or kcnh2 variant

Cohort Study n=157766 26.0 weeks

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a …

Dose: None vs: None Outcome: Incidence of hyperkalemia, mortality 効果: None None

対象集団: Newly diagnosed CKD patients in Denmark

Observational Study n=40

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).

Dose: anti-digoxin antibodies (Fab) vs: pre-treatment Outcome: serum digoxin and clinical outcomes 効果: Fab bound digoxin; no improved clinical outcomes None

対象集団: Chronic digoxin toxicity patients

Other

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, …

Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Other

Potassium supplements or potassium-sparing agents.

Dose: None vs: None Outcome: mineral status 効果: None None

対象集団: hypertensive patients

Key Statistics

研究数

300

参加者数

↑

Positive

グレード

Referenced Papers

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. Other

Open heart 2021 6 件の引用

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Other

Nephrology, dialysis, transplantation … 2018 83 件の引用

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Observational

Clinical toxicology (Philadelphia, … 2016 25 件の引用

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … Other

Therapeutic drug monitoring 2011 17 件の引用

Potassium supplements or potassium-sparing agents. Other

Acta pharmacologica et … 1984 3 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

supplements:: Typically 99 mg/dose (FDA limit per unit)
dashdiettarget:: 4,700 mg/day
whorecommendation:: 3,510 mg/day from food

上限量： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

研究で検討された用量

用量	期間	効果	N
50 mg	1 weeks	Neutral	19
None	26.0 weeks	Mixed	157766
anti-digoxin antibodies (Fab)	--	Neutral	40
None	--	Positive	--
None	--	Mixed	--

推奨摂取タイミング： With meals to reduce GI irritation; divide supplemental doses throughout the day

Safety & Side Effects

報告されている副作用

⚠ Gastrointestinal irritation (nausea, vomiting, diarrhea)
⚠ Hyperkalemia risk in patients with renal impairment
⚠ Cardiac arrhythmias at excessively high serum levels

既知の相互作用

● ACE inhibitors (increased hyperkalemia risk)
● ARBs (increased hyperkalemia risk)
● Potassium-sparing diuretics (increased hyperkalemia risk)
● NSAIDs (may increase potassium retention)

耐容上限摂取量： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Potassium help with Cardiac Arrhythmia?

Based on 5 studies with 300 participants, there is limited but promising evidence that Potassium may support Cardiac Arrhythmia management. Our evidence grade is C (Some Evidence).

How much Potassium should I take for Cardiac Arrhythmia?

Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Potassium?

Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Potassium and Cardiac Arrhythmia?

We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.

に関する他の成分： Cardiac Arrhythmia

Omega-3 Fatty Acids (EPA/DHA) B Magnesium B Coenzyme Q10 (CoQ10) C

Potassium 他の症状・状態について

High Blood Pressure (Hypertension) B

総合評価

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Evidence Strength52%

Moderate confidence

研究の内訳

RCT (0)Meta (0)Other (5)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Cardiac Arrhythmia

詳しく見る

References

[1] Peter Marstrand et al.. Open Heart. 2021. Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. doi:10.1136/openhrt-2021-001670 PubMed
[2] Reimar W Thomsen et al.. Nephrol Dial Transplant. 2018. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. doi:10.1093/ndt/gfx312 PubMed
[3] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
[4] Andrea DeFrance et al.. Ther Drug Monit. 2011. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … doi:10.1097/FTD.0b013e3181fd4c30 PubMed
[5] S Persson. Acta Pharmacol Toxicol (Copenh). 1984. Potassium supplements or potassium-sparing agents. doi:10.1111/j.1600-0773.1984.tb03642.x PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Potassium ： Cardiac Arrhythmia

Embed This Widget

結論

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

一般的な使用量

研究で検討された用量

Safety & Side Effects

報告されている副作用

既知の相互作用

Frequently Asked Questions

Related Evidence

に関する他の成分： Cardiac Arrhythmia

Potassium 他の症状・状態について

References